article thumbnail

Diabetes treatments are improving. Racial disparities are wider than ever

STAT

Despite advancements in insulin treatments over the past three decades, disparities in outcomes have widened among people with diabetes taking them, a new study found.

Diabetes 248
article thumbnail

Large diabetic drug comparison study releases results

European Pharmaceutical Review

Results from the first study comparing four type 2 diabetes medications found that insulin glargine and liraglutide, two popular medications, performed best. If approved as a treatment, the findings give the diabetic population a more positive future, regarding management of their condition. Over 37 million Americans have diabetes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Lupin, Zydus sign licensing pact to co-market Saroglitazar Mg for chronic liver diseases in India

Express Pharma

Saroglitazar Mg was launched in India in September 2013 for the treatment of diabetic dyslipidemia and hypertriglyceridemia in patients with type-2 diabetes not controlled by statins alone. It reduces co-morbidities (dyslipidemia, hypertriglyceridemia, and diabetes mellitus).

article thumbnail

Towards a new understanding of cardiovascular risk in diabetes

pharmaphorum

A new post-hoc analysis from Novo Nordisk of their SUSTAIN 6 and PIONEER 6 studies into semaglutide is looking to help ‘individualise’ treatment for diabetes patients by better predicting their cardiovascular lifetime risk. The two studies included 6,480 people with type 2 diabetes with high cardiovascular risk aged between 50-90 years.

article thumbnail

Zydus NCE drugs will see improved market penetration with new partnerships in India:  GlobalData

Express Pharma

In March 2022, desidustat was approved in India to treat anemia associated with chronic kidney disease (CKD), whereas saroglitazor was approved in June 2013 for diabetic dyslipidemia and hypertriglyceridemia. Moreover, saroglitazar is the world’s first drug to get approval for NASH.

article thumbnail

Automated insulin dosing app Tidepool Loop FDA-cleared

pharmaphorum

The 501(c)3 non-profit Tidepool, which seeks to empower the next generation of innovations in diabetes management, has announced that the US Food and Drug Administration (FDA) has cleared Tidepool Loop, an automated insulin dosing app intended for the management of type 1 diabetes (T1D) in those six years old and above.

article thumbnail

Smartphone-powered trial backs J&J’s Invokana for heart failure

pharmaphorum

It enrolled patients with and without type 2 diabetes and heart failure, to see whether treatment with Invokana (canagliflozin) can improve their symptoms, function and quality of life compared to placebo. billion in 2016 before the product was linked to an increased risk of lower limb amputation.

Diabetes 105